Nasdaq · Biotech stocks database
VCRE (Vicore Pharma Holding AB) stock: $10.35, $2.91B market cap, $39.6M cash, $2.87B EV. Next expected readout: May-27. Lead program: Buloxibutid (Idiopathic Pulmonary Fibrosis (IPF)), Phase 2. Data from Fully Diluted's biotech stocks database.
| Cash | $39.6M |
|---|---|
| Debt | $0.0M |
| Net cash | $39.6M |
| Enterprise value | $2,874.2M |
| Basic shares | 281.5M shares |
| Fully diluted shares | Not disclosed |
| Fully diluted market cap | Not disclosed |
| Cash per share | $0.14 |
Cash figures as of 2026-03-31. Database snapshot: 2026-09-21.
Loading VCRE daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Jun 12 - Jul 24 | Buloxibutid | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.